Lv55
1000 积分 2025-12-30 加入
Discovery of SPH5030, a Selective, Potent, and Irreversible Tyrosine Kinase Inhibitor for HER2-Amplified and HER2-Mutant Cancer Treatment
2天前
已完结
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial
7天前
已完结
Exploring tyrosine kinase inhibitors for HER2-positive breast cancer: comprehensive review on a complete pharmacology-molecular mechanisms, safety profiles, and insights from preclinical and clinical studies
7天前
已完结
New applications and developments in the use of multiplex ligation‐dependent probe amplification
1个月前
已完结
Outcomes that matter to patients with cancer: living longer and living better
1个月前
已关闭
Circulating Tumor DNA in Early Breast Cancer
1个月前
已完结
化疗相关腹泻全程管理中国专家共识(2025年版)
8个月前
已采纳
皖公网安备34019202002308
